公司資料
HUTCHMED 股價、新聞與催化劑
- 股票代碼:
- HCM
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- China and listed in the U
股票表現
12.56 USD (+2.95%)
收盤價
最後更新: 2026年8月17日
1.98B USD
市值
股價為何變動
Following the latest company update, “HUTCHMED Announces ORPATHYS® Plus TAGRISSO® Demonstrated Statistically Significant and Clinically Meaningful Improvements in Progression-Free and Overall Survival in MET-Driven EG…”, HCM closed up 2.95% at $12.56 on Aug 17, 2026. The move occurred in the trading session associated with this clinical readout update.
公司概覽
China-Originated Oncology Company
HUTCHMED is an oncology-focused biopharmaceutical company with commercial products in China and partnered global products. Its strategy combines China commercialization, global partnerships, and internal R&D aimed at differentiated small molecules and newer antibody-targeted modalities.
Commercial Oncology Portfolio
The company's commercial base includes ELUNATE, SULANDA, FRUZAQLA, ORPATHYS, and other oncology products. First-half 2026 growth was led by a rebound in China product sales and geographic expansion of FRUZAQLA outside China, which had approvals or launches in 41 countries.
Late-Stage Regulatory Pipeline
HUTCHMED has multiple late-stage programs across oncology and immunology. Recent progress includes China approval of ELUNATE with sintilimab for second-line kidney cancer, China NDA acceptances for sovleplenib in wAIHA and ITP, ORPATHYS approval in third-line MET-amplified gastric cancer, and positive data for fanregratinib in FGFR2 fusion or rearrangement intrahepatic cholangiocarcinoma.
ATTC Innovation Strategy
The company is investing in antibody-targeted therapy conjugates, or ATTCs, that use antibody targeting to deliver potent small-molecule payloads to tumor cells. HMPL-A251, HMPL-A580, and HMPL-A830 represent a newer platform layer intended to create first-in-class or best-in-class candidates and support multinational partnering opportunities.
未來催化劑
- Topline results from SAFFRON and SANOVO Phase 3 savolitinib studies in the second half of 2026.
- NMPA review of sovleplenib in wAIHA and ITP.
- Global clinical trial initiation for HMPL-A830 in the second half of 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。